10-Q quarterly report · filed Nov 9, 2026

Immunome Inc. (IMNM) Q3 2026 10-Q Quarterly Report

Short answer

Immunome Inc. (IMNM) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$86M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$86M
−49.3% YoY · −17.3% QoQ
EPS (diluted)
−$0.76
−15.2% YoY · −18.8% QoQ

Source: XBRL data from the Immunome Inc. (IMNM) Q3 2026 10-Q on SEC EDGAR. USD.

Immunome Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales or collaboration revenue
  • Net loss $85.8M vs $57.5M YoY, operating loss $90.4M vs $60.1M
  • Highest R&D spend IM-1021 at $9.6M, up $6.7M YoY; lowest IM-1617 at $1.6M, down $3.8M
  • Cash and equivalents $212.8M, marketable securities $248.7M; operating cash use $181.1M for nine months
  • Existing liquidity sufficient for at least 12 months; additional financing needed, with rising development and commercialization costs

Risk Factors

  • Newly added: IM-3050 Lu-177 program, limited qualified radioactive-material suppliers delayed its Phase 1 trial
  • Regulatory: FDA NDA for varegacestat assigned April 28, 2027 PDUFA date, but approval remains uncertain
  • Compliance: EU AI Act exposure, noncompliance penalties up to €35 million or 7% of worldwide annual turnover
  • Operational: Diagnostic radiotracer shipment delays impaired IM-3050 Phase 1 trial commencement
  • Financial: Accumulated deficit $940.9 million, with cash, equivalents and marketable securities funding at least 12 months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Immunome Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.